HLS Share Price Performance

HLS Community Fair Values

HLS Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Key Takeaways Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue. Strategic cost reductions and expansion through partnerships aim to support growth, while share buybacks enhance earnings per share.
View narrative
CA$6.11
FV
19.4% undervalued intrinsic discount
5.16%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
3 days ago author updated this narrative
Your Fair Value
CA$
Current Price
CA$4.9241.8% undervalued intrinsic discount
Growth estimate over
Annual revenue growth rate
%/yr
Decrease
Increase
Advanced

Recent HLS News & Updates

Vascepa Sales In Canada And Cost Cuts Will Transform Prospects

Apr 07 Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.

HLS Therapeutics Inc. Competitors

View more competitors

Canadian Market Performance

0.9%

7.2%

16.9%

6.5%

In the last week, the market has stayed flat, however the Materials sector stood out, gaining 4.6%. Meanwhile, the market is actually up 17% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

HLS Therapeutics Stock Price

HLS Share Price Performance

HLS Community Fair Values

Vascepa Sales In Canada And Cost Cuts Will Transform Prospects

Recent HLS News & Updates

Consensus EPS estimates upgraded to US$0.32 loss

New minor risk - Profitability

First quarter 2025 earnings: EPS misses analyst expectations

HLS Therapeutics Inc. to Report Q1, 2025 Results on May 08, 2025

HLS Therapeutics Inc., Annual General Meeting, Jun 20, 2025

Vascepa Sales In Canada And Cost Cuts Will Transform Prospects

High number of new directors

Full year 2024 earnings: EPS misses analyst expectations

HLS Therapeutics Inc. Competitors

🎢 Opportunities In The Turbulent Transition To Greener Energy

🤖 A.I. Enters the “Show Me The Money” Phase